Pramlintide: A human amylin analogue reduced postprandial plasma glucose, insulin, and C-peptide concentrations in patients with Type 2 diabetes

Diabetic Medicine

Volumn 14, Issue 7, 1997, Pages 547-555

  Thompson, R G ^a   Gottlieb, A ^a   Organ, K ^a   Koda, J ^a   Kisicki, J ^b   Kolterman, O G ^a  

^a AMYLIN PHARMACEUTICALS INC   (United States)

^b Harris Laboratories Inc Lincolnshire   (United States)

Author keywords

Amylin; C peptide; Glucose; Pramlintide; Type 2 diabetes

Indexed keywords

AMYLIN DERIVATIVE; C PEPTIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; LACTIC ACID; ORAL ANTIDIABETIC AGENT; PLACEBO; PRAMLINTIDE; SUSTACAL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET THERAPY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TEST MEAL;

ADULT; AMYLOID; BLOOD GLUCOSE; C-PEPTIDE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LACTIC ACID; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; SINGLE-BLIND METHOD;

EID: 0030843572     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9136(199707)14:7<547::AID-DIA390>3.0.CO;2-U     Document Type: Article

References (25)

1. Koda JE, Fineman M, Rink TJ, Daily GE, Muchmore DB, Linarelli LG. Amylin concentrations and glucose control. Lancet 1992; 339 (8802): 1179-1180.
2. Hartter E, Svoboda T, Ludvik B, Schuller M, Lell B, Kuenburg E, et al. Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans. Diabetologia 1991; 34: 52-54.
3. Brown K, Menius A, Smadefer E, Edwards J, James M. The effects of amylin on change in plasma glucose and gastric emptying following an oral glucose load in conscious dogs. Diabetes 1994; 43 (suppl 1): 172A.
4. MacDonald I, King P, Kong MF, Stubbs T, Perkins A, Moyses C, et al. Infusion of the human amylin analog, AC137, delays gastric emptying in men with IDDM. Diabetologia 1995; 38 (suppl 1): A32.
5. Kolterman OG, Gottlieb A, Moyses C, Colburn W. Reduction of post-prandial hyperglycemia in subjects with Type I diabetes mellitus by intravenous infusion of AC137, a human amylin analogue. Diabetes Care 1995; 18: 1179-1182.
6. Kolterman OG, Schwartz S, Corder C, Levy B, Klaff L, Peterson J, et al. Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM. Diabetologia 1996; 39: 492-499.
7. Thompson RG, Peterson J, Gottlieb A, Mullane J. Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: Results of a multicenter trial. Diabetes 1997; 46: 632-636.
8. Sanke T, Hanabusa T, Nakano Y, Oki C, Okai K, Nishimura S, et al. Plasma islet amyloid polypeptide (amylin) levels and their responses to oral glucose in Type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1991; 34: 129-132.
9. Ludvik B, Lill B, Hartter E, Schnack C, Prager R. Decrease of stimulated amylin release precedes impairment of insulin secretion in Type II diabetes. Diabetes 1991; 40: 1615-1619.
10. Slein MW, Cori GT, Cori CF. A comparative study of hexokinase from yeast and animal tissues. J Biol Chem 1950; 186: 763-780.
11. Percy AJ, Trainor D, Rittenhouse J, Janes S, Koda J. Sensitive two-site enzyme immunoassays for amylin and amylin-like peptides in human plasma. Clinical Chemistry 1996; 42: 576-585.
12. Fineman MS, Koda JE, Percy A, Wareham NJ, Hales CN. Elevation of high molecular weight amylin-like peptides along with proinsulin and 32, 33 split proinsulin in newly diagnosed diabetes (Abstract) Diabetologia, 1994; 37 (suppl 1): A52.
13. Pittner RA, Albrandt K, Beaumont K, Gaeta L, Koda J, Moore C, et al. J Cellular Biochem 1994; 55 (suppl): 19-28.
14. Percy AJ, Trainor D, Blase E, Redalieu E, Koda JE. Development of a sensitive immunoassay for pramlintide, and its use in pharmacokinetic studies. J Clin Lig and Assay 1997; 20: 32-39.
15. Yalow RS, Berson S. Immunoassay of endogenous plasma insulin in man. J Clin Inv 1960; 39: 1157.
16. Marbach E, Weil MH. Rapid enzymatic measurement of blood lactate and pyruvate. Clin Chem 1967; 13: 314.
17. Fleiss JL. The Design and Analysis of Clinical Experiments. New York: Wiley, 1986: 263-290.
18. SAS/STAT User's Guide, 6th edn. Cary NC: SAS Institute Inc., 1990.
19. Horowitz M, Edelbroek MAL, Wishart J, Straathof J. Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects. Diabetologia 1993; 36: 857-862.
20. Young AA, Gedulin B, Vine W, Percy A, Rink, TJ. Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin. Diabetologia 1995; 38: 642-648.
21. Liddle RA, Rushakoff RJ, Horita ET, Baccaria L, Carter JD, Gordfine ID. Physiological role for cholecystokinin in reducing postprandial hyperglycemia in humans. J Clin Invest 1988; 81: 1675-1681.
22. Phillips WT, Schwartz JG, McMahan CA. Reduced post-prandial blood glucose levels in recently diagnosed non-insulin-dependent diabetics secondary to pharmacologically induced delayed gastric emptying. Digestive Diseases and Sciences 1993; 38: 51-58.
23. Phillips WT, Schwarz JG, McMahan CA. Rapid gastric emptying of an oral glucose solution in type 2 diabetic patients. J Nucl Med 1992; 33: 1496-1500.
24. Horowitz M, Fraser R. Disordered gastric motor function in diabetes mellitus. Diabetologia 1994; 37: 543-551.
25. Young AA, Vine W, Gedulin BR, Pittner R, Janes S, Gaeta LSL, et al. Preclinical pharmacology of pramlintide in the rat: comparisons with human and rat amylin. Drug Development Research 1996; 37: 231-248.